Ryanodine receptors (RyR) are classified as high-conductance, intracellular calcium release channels, typically present in the membrane of the sarcoplasmic and endoplasmic reticulum. [1] The major role these channels play are to regulate cell signaling and muscle contraction by releasing calcium ions. [1] There are three major isoforms of the ryanodine receptor (RyR1, RyR2, and RyR3), which are found in different tissues and participate in various signaling pathways involving calcium release from intracellular organelles. [2] RyR1 is responsible for skeletal muscle contraction, RyR2 is responsible for cardiac muscle contraction, and RyR3 is responsible for maintaining calcium homeostasis in the brain and throughout other tissues in the body.
The ryanodine receptors were originally identified in the 1980s and named after the plant alkaloid ryanodine, found in Central and South America. [3] When ryanodine was first found it was investigated to be a potential insecticide due to its ability to induce paralysis amongst insects. [3]
Later research saw that ryanodine had a high binding affinity to the sarcoplasmic reticulum in muscle cells, which allowed researchers to turn ryanodine into a high affinity ligand responsible for finding its purified receptor. [3] The purified receptor turned out to be a calcium release channel, responsible for controlling the movement of calcium from stores in the cardiac and skeletal tissue. [3]
Ryanodine receptors are known as one of the largest ion channels that form multidomain homotetramers. These domains regulate intracellular calcium ions to release from the sarcoplasmic and endoplasmic reticula. [4] These receptors have weights exceeding 2 megadaltons and their structural complexity enables a wide variety of allosteric regulation mechanisms. [5] [6] Due to these receptors size and structure they are able to integrate regulatory signals and readily control the rate of calcium release.
Studies involving cryo-electron microscopy (cryo-EM) have revealed 3-D structures of Ryanodine receptors. It has been shown that RyR's have fourfold symmetry and adopt a mushroom-like structure: a large cytosolic assembly that forms the "cap" and smaller transmembrane regions that form the "stalk", which is embedded into the sarco/endoplasmatic reticulum's membrane. [7] The bulk of the receptors, approximately 80% of the mass, are present in the cytosolic domain, which accounts for the many regulatory interactions. [7] The cytosolic portion of the structure is made up of an extended α-solenoid scaffold which is able to connect regulatory domains to the ion conducting pores found in the transmembrane region. [7] This allows the receptor to gather and read diverse signal inputs. [7] Also, due to the transmembrane region containing ion conducting pores that puts RyR's in the six-transmembrane ion channel superfamily. [7] Additionally, there is a unique domain inserted between the second and third transmembrane helices which interacts intimately with paired EF-hands originating from the α-solenoid scaffold, suggesting a mechanism for channel gating by Ca2+. [8] [7]
Each major ryanodine receptor isoform (RyR1, RyR2, and RyR3) share a similar structure with minor differences that depend on where they are located and how they function, i.e. heart or skeletal muscle. [9]
There are multiple isoforms of ryanodine receptors:
Non-mammalian vertebrates typically express two RyR isoforms, referred to as RyR-alpha and RyR-beta. Many invertebrates, including the model organisms Drosophila melanogaster (fruitfly) and Caenorhabditis elegans , only have a single isoform. In non-metazoan species, calcium-release channels with sequence homology to RyRs can be found, but they are shorter than the mammalian ones and may be closer to inositol trisphosphate (IP3) receptors.
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ryanodine receptors mediate the release of calcium ions from the sarcoplasmic reticulum and endoplasmic reticulum, an essential step in muscle contraction. [8] In skeletal muscle, activation of ryanodine receptors occurs via a physical coupling to the dihydropyridine receptor (a voltage-dependent, L-type calcium channel), whereas in cardiac muscle, the primary mechanism of activation is calcium-induced calcium release, which causes calcium outflow from the sarcoplasmic reticulum. [12]
It has been shown that calcium release from a number of ryanodine receptors in a RyR cluster results in a spatiotemporally-restricted rise in cytosolic calcium that can be visualized as a calcium spark . [13] Calcium release from RyR has been shown to regulate ATP production in heart and pancreas cells. [14] [15] [16]
Ryanodine receptors are similar to the inositol trisphosphate (IP3 or InsP3) receptor, and stimulated to transport Ca2+ into the cytosol by recognizing Ca2+ on its cytosolic side, thus establishing a positive feedback mechanism; a small amount of Ca2+ in the cytosol near the receptor will cause it to release even more Ca2+ (calcium-induced calcium release/CICR). [8] However, as the concentration of intracellular Ca2+ rises, this can trigger closing of RyR, preventing the total depletion of SR. This finding indicates that a plot of opening probability for RyR as a function of Ca2+ concentration is a bell-curve. [17] Furthermore, RyR can sense the Ca2+ concentration inside the ER/SR and spontaneously open in a process known as store overload-induced calcium release (SOICR). [18]
RyRs are especially important in neurons and muscle cells. In heart and pancreas cells, another second messenger (cyclic ADP-ribose) takes part in the receptor activation.
The localized and time-limited activity of Ca2+ in the cytosol is also called a Ca2+ wave. The propagation of the wave is accomplished by the feedback mechanism of the ryanodine receptor. The activation of phospholipase C by GPCR or RTK triggers the production of inositol trisphosphate, which activates of the InsP3 receptor.
A variety of other molecules may interact with and regulate ryanodine receptor. For example: dimerized Homer physical tether linking inositol trisphosphate receptors (IP3R) and ryanodine receptors on the intracellular calcium stores with cell surface group 1 metabotropic glutamate receptors and the Alpha-1D adrenergic receptor [22]
The plant alkaloid ryanodine, for which this receptor was named, has become an invaluable investigative tool. It can block the phasic release of calcium, but at low doses may not block the tonic cumulative calcium release. The binding of ryanodine to RyRs is use-dependent, that is the channels have to be in the activated state. At low (<10 micromolar, works even at nanomolar) concentrations, ryanodine binding locks the RyRs into a long-lived subconductance (half-open) state and eventually depletes the store, while higher (~100 micromolar) concentrations irreversibly inhibit channel-opening.
The diamides, an important class of insecticide making up 13% of the insecticide market, [23] work by activating insect RyRs. [24]
RyRs form docking platforms for a multitude of proteins and small molecule ligands. [8] Accessory proteins bind these channels and regulate their gating, localization, expression, and integration with cellular signaling in a tissue- and isoform-specific manner.
FK506-Binding Proteins (FKBP12 / FKBP12.6) — aka Calstabin-1 and Calstabin-2 — stabilize the closed state of RyRs, preventing pathological Ca²⁺ leak. [11]
The cardiac-specific isoform (RyR2) is known to form a quaternary complex with luminal calsequestrin, junctin, and triadin. [25] Calsequestrin (CASQ) has multiple Ca2+ binding sites that bind with very low affinity, allowing easy ion release. It acts as RyR gate modulators by signaling when Ca2+ stores are full. Triadin and Junctin are sarcoplasmic reticulum (SR) membrane proteins that link RyRs to CASQ and also respond to Ca²⁺ store levels. [26]
Calmodulin (CaM) and S100A1 both bind the same site on RyRs (especially RyR1 and RyR2), but exert opposite effects: Ca²⁺-bound CaM inhibits RyRs while S100A1 enhances its opening. Expression levels and competition between these proteins tune RyR responses to Ca²⁺ signals. [11]
RyR1 mutations are associated with malignant hyperthermia and central core disease. [27] Mutant-type RyR1 receptors exposed to volatile anesthetics or other triggering agents can display an increased affinity for cytoplasmic Ca2+ at activating sites as well as a decreased cytoplasmic Ca2+ affinity at inhibitory sites. [28] The breakdown of this feedback mechanism causes uncontrolled release of Ca2+ into the cytoplasm, and increased ATP hydrolysis resulting from ATPase enzymes shuttling Ca2+ back into the sarcoplasmic reticulum leads to excessive heat generation. [29]
RyR2 mutations play a role in stress-induced polymorphic ventricular tachycardia (a form of cardiac arrhythmia) and ARVD. [10] It has also been shown that levels of type RyR3 are greatly increased in PC12 cells overexpressing mutant human Presenilin 1, and in brain tissue in knockin mice that express mutant Presenilin 1 at normal levels, [30] and thus may play a role in the pathogenesis of neurodegenerative diseases, like Alzheimer's disease. [31]
The presence of antibodies against ryanodine receptors in blood serum has also been associated with myasthenia gravis (i.e., MG). [8] Individuals with MG who have antibodies directed against ryanodine receptors typically have a more severe form of generalized MG in which their skeletal muscle weaknesses involve muscles that govern basic life functions. [32]
Sudden cardiac death in several young individuals in the Amish community (four of which were from the same family) was traced to homozygous duplication of a mutant RyR2 (Ryanodine Receptor) gene. [33] Normal (wild type) ryanodine receptors are involved in CICR in heart and other muscles, and RyR2 functions primarily in the myocardium (heart muscle).
The expression, distribution, and gating of RyRs are modified by cellular proteins, presenting an opportunity to develop new drugs that target RyR channel complexes by manipulating these proteins. Several drugs, such as FK506, rapamycin, and K201, can modify interactions between RyRs and their accessory proteins. [11]
| Drug | Target | Effect | Clinical Use | Concerns |
|---|---|---|---|---|
| FK506, Rapamycin | FKBP-RyR | Disrupts complex, causes leak | Immunosuppressant | Not RyR-specific |
| K201 (JTV519) | FKBP-RyR | Stabilizes complex, prevents leak | Heart Failure (still investigational) | Off-target SERCA inhibition |
| Dantrolene | RyR1, RyR3 | receptor antagonist | MH, spasticity | No effect on RyR2 |
| Doxorubicin, Tricyclic antidepressants | CASQ2 | Reduces Ca²⁺ buffering | Chemotherapy, antidepressants | Cardiotoxicity |
| Ivabradine | Unknown | Increases FKBP12/12.6 levels | Heart Failure (bradycardia) | Indirect mechanistic action |
| Statins | RyR3 upregulation | Myopathy | Hypercholesterolemia | Adverse skeletal muscle effects |
{{cite journal}}: CS1 maint: unflagged free DOI (link){{cite journal}}: CS1 maint: unflagged free DOI (link)